Precision Lung Cancer Logo

Day One: Tuesday July 25, 2017

REGISTRATION & COFFEE

8:00

Introduction and Summary

8:15

Lung Cancer Immunotherapy

8:30

Improved Survival with Erdafitinib and PD-1 Blockade in an FGFR2-driven Lung Cancer GEMM is Mediated by Enhanced Anti-Tumor Immunity


Raluca Verona

Associate Director


Janssen

9:00

PD-1 Inhibition for Lung Cancer

Gregory Lubiniecki
Executive Director, Oncology Clinical Research,

 

 

Merck

9:30

10:00

Opportunities and Challenges in Immunotherapy in Orphan Thoracic Malignancies

Tien Hoang

Medical Director

 

Genentech

Reprogramming Tumor-Associated Macrophages by Targeting PI3K-gamma with IPI-549

 

Jeff Kutok

Chief Scientific Officer

 

Infinity Pharmaceuticals

10:30

Challenges and Solutions to Access Biospecimen Collections Required for Biomarker Discovery and Validation

Pascal Puchois

Chief Executive Officer


Trans-Hit

MORNING REFRESHMENTS & SPEED NETWORKING

10:45

11:30

Developing Potent And Selective Miniaturized Conjugates For The Treatment Of Patients With Solid Tumors

 

Leila Alland

Chief Medical Officer

 

Tarveda

12:00

Overriding Phosphatidylserine-mediated Tumor Immune Suppression to Enhance Immune Checkpoint Therapies

Bruce Freimark

Research Director, Preclinical Oncology

 

Peregrine

12:30

A few reasons why we fail Phase 3 trials in oncology: a couple of examples in lung cancer

 

Adrian Senderowicz

Chief Medical Officer

Cerulean

12:45

TBA

Boyd Mudenda
Associate Vice President

Immunomedics

LUNCH & NETWORKING

1:15

PANEL DISCUSSION

2:15

 

Sergio Santillana
Vice President, Clinical Research

Ariad Pharmaceuticals

 

Lawrence Thomas
Executive Director, Preclinical R&D

Celldex Pharmaceuticals

more to be announced..

Cancer Vaccines

3:00

Novel Investigational RNA-Based Vaccine for the Treatment of NSCLC

 

Eric Block

Associate Director

 

Boehringer Ingelheim

3:30

Optimized cryptic peptides : a universal neoantigen therapeutic cancer approach

 

 

Kostas Kosmatopoulos

CEO, CSO


Vaxon Biotech

AFTERNOON REFRESHMENTS & NETWORKING

4:00

4:30

Glyco-engineering of an anti-PD-L1 antibody

 

Christoph Goletz

Associate Director, Immunomodulation

 

Glycotope

5:00

Utilizing the body’s own immune system to treat lung cancer

 

Giuseppe Del Priore

Chief Medical Officer

 

Tyme Technologies Inc

 

SUMMARY & CLOSE OF DAY ONE

5:30

VIEW NEXT DAY

DOWNLOAD EVENT GUIDE

Complete the form below to download the PDF

NEO SYNTH International House, 24 Holborn Viaduct, London EC1A 2BN

contact@neo-synth.com

(+1) 617.500.5172

Submitting Form...

The server encountered an error.

Request received. Please allow some time for processing - You will receive a manual response within a few hours.

Your details will not be shared with a third party

Copyright © 2017| All content produced by: neo-synth ltd.

DOWNLOAD GUIDE

Complete the form below to download the PDF